carbostyril has been researched along with Metabolic Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Candeias, NR; Gois, PMP; Gonçalves, LMD; Guedes, RC; Leandro, J; Leandro, P; Lopes, RR; Paterna, R; Russo, R; Sousa, PMF; Teixeira, M; Tomé, CS; Vicente, JB | 1 |
| Dai, G; Zhang, Y | 1 |
| Gaikwad, AB; Kadakol, A; Kumar, GS; Malek, V; Pandey, A | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| McIntyre, RS | 2 |
| Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K | 1 |
| Bobmanuel, S; Davies, W; Dratcu, L; Farmer, A; George, M; Rana, T; Singh, M; Turner, M | 1 |
| Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH | 1 |
| Chavez, B; Poveda, RA | 1 |
| Chen, CH; Huang, MC; Lu, ML | 1 |
3 review(s) available for carbostyril and Metabolic Diseases
| Article | Year |
|---|---|
FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Forkhead Box Protein O1; Humans; Metabolic Diseases; Obesity; Quinolones; Therapies, Investigational | 2016 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Metabolic Diseases; Obesity; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
1 trial(s) available for carbostyril and Metabolic Diseases
| Article | Year |
|---|---|
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
7 other study(ies) available for carbostyril and Metabolic Diseases
| Article | Year |
|---|---|
Modulation of Human Phenylalanine Hydroxylase by 3-Hydroxyquinolin-2(1H)-One Derivatives.
Topics: Catalytic Domain; Electron Spin Resonance Spectroscopy; Fluorometry; HEK293 Cells; Humans; Metabolic Diseases; Models, Molecular; Phenylalanine; Phenylalanine Hydroxylase; Phenylketonurias; Quinolones; Surface Plasmon Resonance; Trypsin | 2021 |
The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.
Topics: Antipsychotic Agents; Aripiprazole; Canada; Clinical Trials as Topic; Comorbidity; Drug Utilization; Drug Utilization Review; Humans; Metabolic Diseases; Mood Disorders; Piperazines; Psychotic Disorders; Quinolones; Risk Factors | 2010 |
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden | 2011 |
A UK panel consensus on the initiation of aripiprazole for the treatment of bipolar mania.
Topics: Acute Disease; Anhedonia; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; Humans; Long-Term Care; Metabolic Diseases; Patient Participation; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Sexual Dysfunction, Physiological; Treatment Outcome | 2012 |
Aripiprazole in schizophrenia: consensus guidelines.
Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |